Advanced Search
13 October 2020

Our scientists presented at the 3rd Scientific Summit on Tobacco Harm Reduction: Novel products, Research & Policy on September 24, 2020 by pre-recording themselves presenting their posters. In this video, Roulet focuses on the IQOS uptake and history of tobacco product use with findings from cross-sectional surveys in Japan, Italy, and Germany.

Return to the conference page or you can watch all the presentations below:

A proposed approach for evaluating harm reduction in adult smokers after switching from cigarettes to tobacco heating system (THS): biomarkers of potential harm  - Dr. Christelle Haziza

Toxicological assessment of flavored e-liquids in Sprague Dawley rats in an OECD sub chronic inhalation study complemented by systems toxicology endpoints - Dr. Davide Sciusco

Systems toxicology assessment of a representative e-liquid formulation by using human primary bronchial epithelial cells - Dr. Diego Marescotti 

Tobacco heating system 2.2 in mild to moderate chronic obstructive pulmonary disease subjects: An exploratory analysis - Dr. Francesco Sergio

IQOS uptake and history of tobacco product use: findings from cross-sectional surveys in Japan, Italy, and Germany - Steve Roulet

Related Articles

Studies in Japan

Studies in Japan

Understanding how to achieve risk reduction for smokers
grey thumb

Perception & Behavior
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

Our RRPs

Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.